FIPB clears GlaxoSmithKline's Rs 6,400 cr FDI proposal

FIPB today cleared Rs 6,400 crore FDI proposal of GlaxoSmithKline to acquire additional 24.33 per cent stake in its India arm.

"The proposal of GlaxoSmithKline has been cleared," said a source after the meeting of Foreign Investment Promotion Board, headed by Economic Affairs Secretary Arvind Mayaram.

The Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33 per cent stake or 2.06 crore equity shares in GlaxoSmithKline Pharmaceuticals Ltd through an open offer.

The acquisition will result in foreign exchange inflow of Rs 6,400 crore, as per the firm's proposal to FIPB.

GlaxoSmithKline Pharmaceuticals is already majority owned and controlled by the GSK Group.

After the purchase, holding of the promoter group firms in the Indian subsidiary will go up to 75 per cent from the current level of 50.67 per cent.

The open offer for tendering of shares is scheduled to remain open from February 7-21.

GSK Pharma makes, distributes and trades a variety of drugs. Its portfolio includes prescription medicines and vaccines across areas such as anti-infectives, dermatology, and gynaecology.

The company employs more than 5,000 people and generated more than Rs 2,600 crore turnover in the financial year ended December 31, 2012.

FDI inflow in the pharma sector during the April-October period totalled Rs 5,956 crore (USD 1.08 billion).

In September, the government cleared the Rs 5,168-crore deal of the US-based Mylan Inc for acquiring Bangalore-based pharma firm Agila Specialties, a subsidiary of Strides Arcolab.

In 2008, Japanese firm Daiichi Sankyo had bought out the country's largest drug maker Ranbaxy for USD 4.6 billion. US-based Abbot Laboratories had acquired Piramal Health Care's domestic business for USD 3.7 billion.

India allows 100 per cent FDI in pharma sector through automatic approval route in the new projects, but foreign investment in the existing companies is allowed only through the FIPB approval.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Sebi’s latest ban on 260 entities plugs a major loophole for stock manipulation

    Last week, the capital market regulator, Securities and Exchange Board of India (Sebi) banned 260 entities from dealing in the securities market for m

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Kumar Jain

Nuances in managing joint ventures

This is an age of collaboration. A seemingly simple device ...

Kuruvilla Pandikattu SJ

Finding the missing child of Christmas

Christmas is basically the feast of a helpless child. The ...

Shona Adhikari

Why Indian art auctions are here to stay

With Christie’s second India sale just over in Mumbai, we ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture